Former Chief Operating Officer · IONIS PHARMACEUTICALS INC (IONS)

B. Lynne Parshall

A named executive officer of IONIS PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$5,737,388

Salary $91,023Stock awards $1,377,350

FY2017: $5,360,037

2nd of 6 named executive officers at Ionis Pharmaceuticals by FY2018 total.

6 named officers on file for IONIS PHARMACEUTICALS, FY2018

B. Lynne Parshall’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • IONS’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how IONIS PHARMACEUTICALS’s whole pay program stands against its peers

  • IONIS PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IONS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2019 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get B. Lynne Parshall’s full pay file as a PDF — free

More than this page: up to 10 years of B. Lynne Parshall’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

B. Lynne Parshall compensation by year

IONIS PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as IONIS PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$712,676$734,056$91,023
Bonus$801,761$668,909$0
Stock awards$786,549$942,853$1,377,350
Option awards$3,143,869$2,968,317$3,083,015
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$29,773$45,902$1,186,000
Total$5,474,628$5,360,037$5,737,388

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IONIS PHARMACEUTICALS INC DEF 14A filed April 26, 2019, accession 0001140361-19-007625, and prior-year filings. Open the filing on EDGAR.

How this page was built: the IONIS PHARMACEUTICALS INC filed document, accession 0001140361-19-007625. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.

$5.5M
$5.4M
$5.7M
FY16
FY17
FY18
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU23,016$1,244,245—
RSU14,704$794,898—
RSU8,962$484,486—
RSU5,519$298,357—
RSU3,555$192,183—
Option2,760—$61.57
Option29,128—$61.68
Option61,269—$47.34
Option103,575—$49.25
Option16,000—$42.88

Per the Outstanding Equity Awards at Fiscal Year-End table in IONIS PHARMACEUTICALS INC's FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

32 Form 4 lines since the FY2018 proxy (filed April 26, 2019)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-04-15Sale10b5-14,466$76.1951,878
2026-04-15Sale10b5-1534$76.9751,344
2026-02-11Sale10b5-15,000$82.7256,344
2025-10-15Sale10b5-15,000$71.7461,344
2025-09-02Sale10b5-110,750$50.4275,594
2025-09-02Sale10b5-19,250$51.4966,344
2025-08-06Sale10b5-1400$42.6386,344
2025-08-06Sale10b5-14,600$41.8786,744

The 8 most recent of 32 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

IONIS PHARMACEUTICALS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Stanley CrookeChairman, President, Chief Executive Officer$7,625,579
B. Lynne Parshall · this pageFormer Chief Operating Officer$5,737,388
Brett MoniaChief Operating Officer$4,275,699
Richard GearySenior Vice President, Development$2,969,196
Patrick O'NeilSenior Vice President, Legal, General Counsel and Corporate Secretary$2,795,214
Elizabeth HougenSenior Vice President, Finance and Chief Financial Officer$2,794,066

Board service

IONIS PHARMACEUTICALS board · FY2021–FY2025
Director compensation in US dollars, as IONIS PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$90,000$208,487$240,293$0$538,780
FY2023$90,000$192,131$255,907$0$538,038
FY2022$90,000$202,974$274,724$244,641$1,037,339
FY2021$86,250$213,587$273,240$615,522$1,188,599

Each year as the company reported it in IONIS PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: IONIS PHARMACEUTICALS pays directors a $60,000 cash retainer and $450,000 in Options and RSUs. As stated in IONIS PHARMACEUTICALS's FY2025 proxy.

Committees

Compliance (Chair) · Finance

The full IONIS PHARMACEUTICALS compensation record

free company brief

This page is one person within IONIS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IONIS PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IONIS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

B. Lynne Parshall's compensation dossier · One-time report. No refunds.